While additional muscle benefits of anti-RANKL treatment are unlikely in GC-treated people with DMD, the use of anti-RANKL alone to improve muscle integrity would avoid the use GC and their related skeletal side effects. The gene discussed is TNFSF11; the disease is Duchenne muscular dystrophy.